1 Min Read
Nov 13 (Reuters) - Protalix Biotherapeutics Inc
* Protalix Biotherapeutics receives positive opinion for orphan designation for PRX-102 for the treatment of Fabry disease in the European Union Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.